Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296229 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
A NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT02296229 is a NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 220 participants, above the 99-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02296229, a NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Studying quality of life in patients undergoing stereotactic body radiation therapy may help identify the long-term effects of treatment on patients with prostate cancer.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- RADIATION stereotactic body radiation therapy
- OTHER quality-of-life assessment
- DRUG androgen deprivation therapy
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2014-01-27 |
| Est. Completion | 2027-01-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296229
The ClinicalTrials.gov registry entry for NCT02296229 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (122% higher). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02296229 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02296229 about?
NCT02296229 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer". This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of rad...
What is the current status of trial NCT02296229?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2014-01-27. Estimated completion is 2027-01-27.
What conditions does trial NCT02296229 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer.
What interventions are being tested in trial NCT02296229?
The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic body radiation therapy (RADIATION), quality-of-life assessment (OTHER), androgen deprivation therapy (DRUG).
Who is sponsoring clinical trial NCT02296229?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296229 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
ACTIVE NOT RECRUITING · NA
-
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
COMPLETED · NA
-
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
COMPLETED · NA
-
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
COMPLETED · NA
-
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
COMPLETED · NA
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.